Upcoming Results from Clinical Trials - Research Report on Gilead Sciences, Celgene Corporation, Sinovac Biotech, NPS Pharmaceuticals and ZIOPHARM Oncology

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

Gilead Sciences recently presented results from a new study indicating that its angina drug Ranexa was able to reduce the frequency of chest pain of patients with diabetes. Ranexa is already approved to treat patients with angina, a type of chest pain associated with heart disease, but the new study was done to test if the drug can be used for diabetics, who can experience more complications as opposed to other drug patients. According to Dr. Mikhail Kosiborod, the drug may also have a glucose lowering effect aside from being an anti-anginal drug. If this effect is confirmed in future studies, patients with diabetes and angina may receive dual benefits from the drug. Ranexa has been providing substantial gains for Gilead, contributing $373 million in sales in 2012. If approved for as a drug for patients with diabetes, the drug may be able to further boost sales. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/9696_GILD]

--

Celgene Corporation Research Report

The Bank of America reiterated its Buy rating on Celgene and increased its price target from $113 to $127 following the results of a commissioned statistical analysis that the firm completed regarding Celgene's MM-020 study for its myeloma drug, Revlimid. The study will expand the indication of the drug from relapsed/refractory myeloma to a broader range of patients who are newly diagnosed with multiple myeloma. Bank of America has reversed its bearish stance on the outcome of the study but maintains the crucial effect of the results on the company's shares. Looking forward, Celgene expects Revlimid net product sales to increase 10 percent year-over-year to a range of $4,100 to $4200 million. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/7541_CELG]

--

Sinovac Biotech Ltd. Research Report

Sinovac's shares jumped as much as 60 percent in early trading as the China-based company presented late-stage trials of its experimental vaccine for hand, mouth and foot disease (HFMD). The study met its end goal of preventing infection in infants between 6 to 35 months. The results showed that 95.4 percent of vaccinated subjects showed immune response. According to Aegis Capital analyst Raghuram Selvaraju the vaccine is likely to get approval from Chinese regulators by the first quarter of 2013 and may be launched in the middle of 2014. Cases of HFMD total at around 2 million in China and the vaccination program could reach at least 10 million people. This shows how much potential gains the vaccines can provide for the company. The Full Research Report on Sinovac Biotech Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/846e_SVA]

--

NPS Pharmaceuticals, Inc. Research Report

NPS Pharmaceuticals recently launched its newly approved product, Gattex, the first and only long-term treatment for adult short bowel syndrome. To expand its potential further, NPS Pharmaceuticals is currently conducting a new study, which will expand the uses of the drug for children. Aside from this, NPS Pharmaceuticals is on its way to submit its Biologics License Application in the second half of 2013 for Natpara, a replacement therapy for hypoparathyroidism. The final study will be conducted this month for Natpara with results expected in the second quarter of 2013. With a newly launched product and another product underway, NPS Pharmaceuticals may be on its way to achieve strong profitability. The company's Sensipar royalty agreement with Amgen also generates $63 million in annual cash flows, helping the company stay afoot. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/4519_NPSP]

--

ZIOPHARM Oncology, Inc. Research Report

ZIOPHARM Oncology recently initiated Phase 2 Study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with advanced breast cancer. According to ZIOPHARM CEO Jonathan Lewis, "The study has exciting potential, both for this difficult-to-treat indication and for our synthetic biology platform… we believe the combination of Ad-RTS IL-12 and palifosfamide has the potential to be quite impactful in breast cancer." Furthermore, Ziopharm has told investors to expect phase II study results for its sarcoma drug palifosfamide in the last week of March. As the deadline looms, many may expect the company to gain plenty of interest from analysts and investors with its promising pipeline and prospects. The Full Research Report on ZIOPHARM Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/71e2_ZIOP]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Joe Thomas
Email: [email protected]
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source